Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

05/19/2014

BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

05/05/2014

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financial information
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/30/2014

BioAlliance Pharma Publishes its first Shareholder Newsletter

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/29/2014

BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company

— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]

• 2014
• Financial operations
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/16/2014

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

04/14/2014

Publication of the 2013 Registration Document

BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

• 2014
• Financial information
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/08/2014

BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financials and Corporate
• General meetings
• Press releases

Tags: Financials & Corporate

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

Tags: Other

04/02/2014

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

Tags: Other

04/01/2014